Lenti-D gene therapy: Additional Phase II/III data

Additional data from 17 patients ages <=17 with childhood CALD in the open-label, international Phase II/III Starbeam (ALD-102) trial showed that bluebird bio’s Lenti-D gene therapy did not lead to an...